Home > Pharmaceuticals > Pneumonia Therapeutics Market Outlook, Share, Growth, Forecast to 2031
Straits Research

Pneumonia Therapeutics Market

Pneumonia Therapeutics Market: Information by Drug (Antibacterial), Age Group (Adult), Infection Mode (Hospital Acquired), Distribution Channel (Retail), and Region - Forecast till 2031

Table of Content Download Sample

Market Overview

Pneumonia is a prevalent form of an acute respiratory infection that affects the alveoli of the lungs. Fungi, bacteria cause the disease, or viruses mediated infection. When an individual has pneumonia, the clinical manifestations can be as severe as painful breathing and oxygen deficiency due to limited intake for the patients; the alveolar sacs are filled with pus and fluid and chest pain, dry cough, and fever. In some instances, the disease can be as severe as fatal for patients.

The global pneumonia therapeutics market size was valued at USD 19.33 billion in 2022. It is projected to reach USD 37.69 billion by 2031, growing at a CAGR of 7.7% during the forecast period (2023–2031).

Market Snapshot

market snapshot
Base Year
: 2022
Study Period
: 2021-2031
: 7.7 %
Fastest Growing Market
: Asia Pacific
Largest Market
: North America
Market Size
: USD 37.69 billion by 2031
Get more information on this report Download Sample Report

Market Dynamics

The Growing Prevalence of Pneumonia is Driving the Therapeutics Market

The growing prevalence of pneumonia has been a significant driver of the pneumonia therapeutics market. Pneumonia is the biggest cause of mortality owing to an infectious disease in children worldwide. For instance, according to reports from the World Health Organization, pneumonia can be held accountable for 808 694 deaths under the age of 5 in 2017, which corresponds to 15% of all children's deaths within the age bracket. Further, as per the American thoracic society, in the U.S., pneumonia can be held responsible for the most common cause of hospital admissions other than pregnancy. Statistically, it can be estimated that about 1 million adults in the U.S. seek medical care due to pneumonia annually, and a further, 50,000 die from it. Thus, owing to such high prevalence, there is a massive demand for appropriate therapeutics in the market. This is boosting the global market significantly.

Additionally, as per the Center for Disease Control and Prevention (CDC), mortality due to pneumonia is astonishingly high at 14.7 deaths reported per 100,000 population. Thus, this increases the demand for therapeutic products from the market as due to high mortality, the management of diseases becomes significantly essential. These factors influence market growth directly.

Increasing Funding for New Product Development to Address Disease Management Drives Market Growth

The high severity of pneumonia, coupled with high demand from the market, has boosted the R&D of new therapeutics and vaccines for addressing pneumonia. Further, this has resulted in propelling market growth projectile. For instance, at present, different companies operating in the pneumonia therapeutics market, which includes market giants like Merck, Pfizer, and GSK, are channelizing huge capital and putting enormous efforts in such R&D activities. This is further supported by successful clinical trials and regulatory approvals from concerned authorities. For instance, in February 2020, the U.S. FDA accepted a supplemental new drug application for Recarbrio to treat adults with ventilator-associated and hospital-acquired bacterial pneumonia. Thus, the introduction of such new drug molecules and support and approval from regulatory bodies augment market growth over the forecast period.

Moreover, a consistent increase in funding opportunities in research for the development of new products is anticipated to broaden the growth scope over the coming years. For instance, the Bill & Melinda Gates Foundation is one of the funding bodies that aim to address neonatal pneumococcal disease and promote the development of new vaccines.

Segmental Analysis

Therapeutic Drugs Account for the Largest Revenue Share

The therapeutic drugs have majorly opted means of treatment for pneumonia infection. Therapeutic drugs include penicillin, cephalosporins, fluoroquinolones, tetracyclines, amoxicillin, vancomycin, and clavulanic acid. For instance, penicillin is a very widely used antibiotic to treat pneumonia caused by Pneumococcal pneumonia infection. Moreover, antibacterial drugs such as Macrolide, Quinolones are also used prevalently. Further, according to the American Thoracic Society 2019, viral pneumonia is one of the major causes of infants' hospitalization in the world. Thus, the rising prevalence of viral pneumonia drives the demand for antiviral therapeutics drugs. However, the drugs segment is anticipated to keep its large market share owing to an estimated steady growth during the forecast period. This can be attributed to the growing generic drugs industry that is contributing to the market. Further, recent patent exposures of branded drugs and the cost-effectiveness of generics are major factors that add to the market's advantage. 

However, owing to the wide use of antibiotics, significant drug resistance has been recognized lately. Thus, therapeutic drugs such as penicillin are still in use but have minimal application. This has fueled the growth of the vaccine segment. Further, growing awareness amongst people due to government and market players' continuous efforts has also boosted the segment growth. For instance, the Center for Disease Control and Prevention (CDC) strongly recommends annual vaccination of every individual with the pneumonia vaccine to measure disease management.

Booming E-commerce boosts the Online Pharmacies Segment within Various Distribution Channels

The online pharmacy segment is expected to witness a boost during the forecast period. This is owing to the recent boom in the e-commerce business across the globe during the COVID-19 pandemic. Further, online pharmacies' significant advantages have also played a major beneficial role in the segmental market. For example, online pharmacies offer products at a reasonable and cheaper price than offline stores, the unavailability of products is not an issue in the online medium, and very less additional cost are significant benefits of the segment.

Additionally, online pharmacies offer accessibility to people with limited mobility at a very affordable price and often provide doorstep delivery within a short time span. These factors cumulatively promote the online pharmacy segment of the pneumonia therapeutics market during the forecast timeframe.

Regional Analysis

North American Regional Market Dominates Globally

The North American global market dominates the global market in terms of revenue. This market dominance can be reasoned with several factors. The global incidence of pneumonia is a primary factor that fuels market growth; however, certain factors explicitly boost the regional market. Additionally, rising awareness amongst people in the region regarding the various therapeutic options available for pneumonia also adds significant advantages to the market.

Further, significant players in the region such as Pfizer, Mylan, GSK provide a home-state advantage to the region. These players are constantly into the R&D of new therapeutics and vaccines to address the rising pneumonia cases. These cumulatively boost the market to attain dominance.

APAC Market to Witness Flourishing Growth During Forecast Period

The Asia Pacific market is expected to witness steady growth during the forecast period. This is primarily due to the burden of pneumonia in regional countries. For instance, the World Health Organization (WHO) estimates an incidence rate of 0.37 cases of clinical pneumonia per child per year.

Further, WHO suggests that India can be accounted for 36% of all cases in the WHO Southeast Asia region. This has surged the demand for therapeutics in the market. Further, other factors in developing countries such as India, China, and Japan, such as improved diagnosis rate, rapidly aging populations, high levels of pollution, and continuous government pressure to address disease management, significantly boost the regional market.

Pneumonia Therapeutics Market Regional Analysis
Regional Growth Insights Download Free Sample

Top Key Players of Pneumonia Therapeutics Market

  1. Abbott Laboratories
  2. Allergan
  3. AstraZeneca
  4. Bayer
  5. Cipla
  6. GlaxoSmithKline Plc.
  7. Lupin Pharmaceuticals Ltd.
  8. Merck
  9. Mylan
  10. Novartis AG
  11. Pfizer, Inc.

Report Scope

Report Metric Details
CAGR 7.7%
Forecast Period 2023-2031
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered
  1. By Drug Class
    1. Vaccines
    2. Therapeutic Drugs
      1. Antibacterial Drugs
      2. Antiviral Drugs
      3. Antifungal Drugs
      4. Others
  2. By Age Group
    1. Pediatric
    2. Adult
    3. Geriatric
  3. By Mode of Infection
    1. Hospital-acquired pneumonia (HAP)
    2. Community-acquired pneumonia (CAP)
    3. Ventilator-associated pneumonia (VAP)
  4. By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
Geographies Covered
  • North America
  • Europe
  • APAC
  • Middle East and Africa

Recent Developments

  • In June 2019, Merck& Co. were awarded the U.S. FDA approval for their Zerbaxa drug which can be used for the treatment of ventilator-associated pneumonia and hospital-acquired bacterial pneumonia.

Pneumonia Therapeutics Market Segmentation

By Drug Class

  • Vaccines
  • Therapeutic Drugs
    • Antibacterial Drugs
    • Antiviral Drugs
    • Antifungal Drugs
    • Others

By Age Group

  • Pediatric
  • Adult
  • Geriatric

By Mode of Infection

  • Hospital-acquired pneumonia (HAP)
  • Community-acquired pneumonia (CAP)
  • Ventilator-associated pneumonia (VAP)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • Americas
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions (FAQs)

What is the growth rate for the Pneumonia Therapeutics Market?
Pneumonia Therapeutics Market size will grow at approx. CAGR of 7.7% during the forecast period.
Some of the top industry players in Pneumonia Therapeutics Market are, Abbott Laboratories, Allergan, AstraZeneca, Bayer, Cipla, GlaxoSmithKline Plc., Lupin Pharmaceuticals Ltd., Merck, Mylan, Novartis AG, Pfizer, Inc., etc.
In the Pneumonia Therapeutics Market, North America has established itself as the market leader with a significant market share.
The Asia Pacific region has experienced the highest growth rate in the Pneumonia Therapeutics Market.
The global Pneumonia Therapeutics Market report is segmented as follows: By Drug Class, By Age Group, By Mode of Infection, By Distribution Channel
Price Starts From
USD 995

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Want to learn more about recent trends and data ?
They Already Trust Us :
Nippon Becton Dickinson
Argon Medical Devices
Johnson & Johnson
Need Assistance?
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the MarketĀ in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track sales in the global and country-specific Market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Report Snapshot
Looking For Custom Report ?
Check Our License Options :

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers